Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria.

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment ...

Pharmaceutical major Sun Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central ...

Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...

For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

One poster will share pooled INTEGUMENT data of ZORYVE ® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Arcutis Biotherapeutics is advancing in alopecia areata and atopic dermatitis with ZORYVE. Learn why ARQT stock offers growth ...

Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by ...